EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar?

Milo Gatti iD, Matteo Rinaldi iD, Cecilia Bonazzetti iD, Antonio Siniscalchi, Tommaso Tonetti, Simone Ambretti, Maddalena Giannella, Pierluigi Viale, Federico Pea iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Milo Gatti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Pseudomonas Infections, Cephalosporins, Pseudomonas aeruginosa, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NextGeneration EU-MUR PNRR Extended Partnership.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the clinical usefulness of a therapeutic drug monitoring (TDM)-guided strategy for attaining an aggressive pharmacokinetic/pharmacodynamic (PK/PD) target of continuous infusion (CI) ceftolozane/tazobactam monotherapy in patients having Pseudomonas aeruginosa infections.

Methods

We performed a pre-post quasi-experimental study including adult patients with documented P. aeruginosa bacteraemia and/or pneumonia who were treated with CI ceftolozane/tazobactam monotherapy tailored by means of a TDM-guided strategy in the period 1 November 2023 to 31 July 2024 (post-intervention phase) compared with patients receiving standard management with CI ceftolozane/tazobactam monotherapy in the period 1 April 2022 to 31 October 2023 (pre-intervention phase). Clinical outcomes were compared between pre- and post-intervention phase. Univariate and multivariate analyses were performed for identifying variables associated with microbiological failure.

Results

Eighty-five patients (48 in pre- and 37 in post-intervention phase) were included. Demographics and clinical features were similar in both groups. No significant difference emerged between groups in terms of microbiological eradication (P = 0.10), 30 day resistance to ceftolozane/tazobactam (P = 0.37), clinical cure (P = 0.26) and 30 day mortality rate (P = 0.79). All patients in the post-intervention phase attained an optimal PK/PD target, allowing the use of a lower ceftolozane/tazobactam CI daily dosing regimen compared with the pre-intervention phase (3.0 g/1.5 g versus 6.0 g/3.0 g; P = 0.06). The only independent predictors of microbiological failure were difficult-to-treat resistant P. aeruginosa isolates in the pre-intervention group (OR 6.99; 95% CI 1.34–36.55), and a ratio of partial pressure of arterial oxygen to fraction of oxygen in the inhaled air (Pao2/Fio2 ratio) <200 in the post-intervention group (OR 18.00; 95% CI 1.86–174.22).

Conclusions

Our TDM-guided strategy of CI ceftolozane/tazobactam was cost-effective in attaining an aggressive PK/PD target of ceftolozane against susceptible P. aeruginosa strains with lower than standard daily doses without compromising efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas InfectionsCephalosporinsPseudomonas aeruginosaAnti-Bacterial AgentsTazobactamDrug MonitoringHumansMaleFemaleMiddle AgedAgedAdultTreatment OutcomeBacteremiaInfusions, IntravenousMicrobial Sensitivity TestsAged, 80 and over

Substanzen

CephalosporinsAnti-Bacterial AgentsTazobactamceftolozane, tazobactam drug combination

Autor:innen und Institutionen

  • Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, Bologna 40138, Italy.
  • Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Anesthesia and Intensive Care Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Division of Anesthesiology, Department of Anesthesia and Intensive Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Operative Unit of Microbiology, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

ORCID-Profile: Milo Gatti, Matteo Rinaldi, Cecilia Bonazzetti, Federico Pea

Förderung

  • NextGeneration EU-MUR PNRR Extended Partnership

Zitieren

APA

Gatti, M., Rinaldi, M., Bonazzetti, C., Siniscalchi, A., Tonetti, T., Ambretti, S., Giannella, M., Viale, P., & Pea, F. (2025). A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar?. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf098

Vancouver

Gatti M, Rinaldi M, Bonazzetti C, Siniscalchi A, Tonetti T, Ambretti S, et al. A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar?. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf098

BibTeX
@article{Gatti2025,
  author = {Gatti, Milo and Rinaldi, Matteo and Bonazzetti, Cecilia and Siniscalchi, Antonio and Tonetti, Tommaso and Ambretti, Simone and Giannella, Maddalena and Viale, Pierluigi and Pea, Federico},
  title = {A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar?},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf098}
}
Kostenlos starten →